Sunday, August 14, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

KAIST researchers engineer a bacterial strain capable of producing lutein

by Medical Finance
in News
New protocol can develop safe, efficient pluripotent stem cell-based therapies for macular degeneration
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

A research group at KAIST has engineered a bacterial strain capable of producing lutein. The research team applied systems metabolic engineering strategies, including substrate channeling and electron channeling, to enhance the production of lutein in an engineered Escherichia coli strain. The strategies will be also useful for the efficient production of other industrially important natural products used in the food, pharmaceutical, and cosmetic industries.

Lutein is classified as a xanthophyll chemical that is abundant in egg yolk, fruits, and vegetables. It protects the eye from oxidative damage from radiation and reduces the risk of eye diseases including macular degeneration and cataracts. Commercialized products featuring lutein are derived from the extracts of the marigold flower, which is known to harbor abundant amounts of lutein. However, the drawback of lutein production from nature is that it takes a long time to grow and harvest marigold flowers. Furthermore, it requires additional physical and chemical-based extractions with a low yield, which makes it economically unfeasible in terms of productivity. The high cost and low yield of these bioprocesses has made it difficult to readily meet the demand for lutein.

These challenges inspired the metabolic engineers at KAIST, including researchers Dr. Seon Young Park, Ph.D. Candidate Hyunmin Eun, and Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering. The team’s study entitled “Metabolic engineering of Escherichia coli with electron channeling for the production of natural products” was published in Nature Catalysis on August 5, 2022.

This research details the ability to produce lutein from E. coli with a high yield using a cheap carbon source, glycerol, via systems metabolic engineering. The research group focused on solving the bottlenecks of the biosynthetic pathway for lutein production constructed within an individual cell. First, using systems metabolic engineering, which is an integrated technology to engineer the metabolism of a microorganism, lutein was produced when the lutein biosynthesis pathway was introduced, albeit in very small amounts.

To improve the productivity of lutein production, the bottleneck enzymes within the metabolic pathway were first identified. It turned out that metabolic reactions that involve a promiscuous enzyme, an enzyme that is involved in two or more metabolic reactions, and electron-requiring cytochrome P450 enzymes are the main bottleneck steps of the pathway inhibiting lutein biosynthesis.

To overcome these challenges, substrate channeling, a strategy to artificially recruit enzymes in physical proximity within the cell in order to increase the local concentrations of substrates that can be converted into products, was employed to channel more metabolic flux towards the target chemical while reducing the formation of unwanted byproducts.

Furthermore, electron channeling, a strategy similar to substrate channeling but differing in terms of increasing the local concentrations of electrons required for oxidoreduction reactions mediated by P450 and its reductase partners, was applied to further streamline the metabolic flux towards lutein biosynthesis, which led to the highest titer of lutein production achieved in a bacterial host ever reported. The same electron channeling strategy was successfully applied for the production of other natural products including nootkatone and apigenin in E. coli, showcasing the general applicability of the strategy in the research field.

“It is expected that this microbial cell factory-based production of lutein will be able to replace the current plant extraction-based process,” said Dr. Seon Young Park, the first author of the paper. She explained that another important point of the research is that integrated metabolic engineering strategies developed from this study can be generally applicable for the efficient production of other natural products useful as pharmaceuticals or nutraceuticals.

“As maintaining good health in an aging society is becoming increasingly important, we expect that the technology and strategies developed here will play pivotal roles in producing other valuable natural products of medical or nutritional importance,” explained Distinguished Professor Sang Yup Lee.

Source:

The Korea Advanced Institute of Science and Technology (KAIST)

Journal reference:

10.1038/s41929-022-00820-4

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Bacterial biofilms use a developmental patterning mechanism seen in plants and animals

Predatory bacterium can sculpt its own shape to fit inside the prey

by Medical Finance
August 14, 2022
0

Scientists have found that a predatory bacterium, capable of invading and consuming harmful bugs such as E.coli and Salmonella, can...

Bacterial biofilms use a developmental patterning mechanism seen in plants and animals

Fecal microbiota transplant can reverse hallmarks of aging in mice

by Medical Finance
August 14, 2022
0

In the search for eternal youth, poo transplants may seem like an unlikely way to reverse the aging process. However,...

UMass Amherst professor receives $2 million NIH MIRA grant for trailblazing research

Key mechanism that increases drug tolerance among microbial communities revealed

by Medical Finance
August 14, 2022
0

Research from the Francis Crick Institute has revealed a key mechanism which increases tolerance to drugs amongst microbial communities. The...

Researchers study immune cell invasion process in living fruit fly embryos

Researchers study immune cell invasion process in living fruit fly embryos

by Medical Finance
August 14, 2022
0

To fight infections and heal injuries, immune cells need to enter tissue. They also need to invade tumors to fight...

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

by Medical Finance
August 14, 2022
0

Mechanical engineering and materials science professor David Needham has shown that a slight increase in solution pH might be all...

Study: Safety, tolerability, and viral kinetics during SARS-CoV-2 human challenge. Image Credit: Jirsack / Shutterstock.com

SARS-CoV-2 human challenge study offers novel insights into viral kinetics

by Medical Finance
August 14, 2022
0

In a recent Nature Portfolio preprint*, researchers discuss the results of a human challenge study to provide novel insights into the...

Next Post
Scientists discover a division of labor between genetic switches

Research highlights the crucial role of other living primates as models for understanding human evolution

Manipulating voltage patterns in tumor cells reduces breast cancer metastasis in animal models

Natural compound found in cardamom shows promise for treating triple-negative breast cancer

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • 78486183 620x480
    Rice University researchers model a key mechanism by which DNA replicates
  • Study: An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Image Credit: Kateryna Kon/Shutterstock
    ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply